(Bloomberg) — Gilead Sciences Inc. (Nasdaq:GILD), basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B.
Even with some promising signs in early trials, the biggest biotechnology firm in the world faces long odds in finding a way to rid humanity of the diseases. And it’s unclear whether a cure for either virus would produce the kind of lucrative return that Gilead has earned from its treatments for hepatitis C.
The Foster City, Calif.-based drugmaker has more than doubled its drug sales since 2013 after introducing Sovaldi and Harvoni, which cure more than 90 percent of patients with the liver virus in a matter of weeks. Gilead’s success also has left it with $8.61 billion in cash on hand, and the drumbeat is getting louder for the company to make a large acquisition to support continued growth.
The biotech giant’s executives say Gilead is trying to maintain its position on the front lines of battle against the viral illnesses, even as it branches out into new disease areas such as cardiovascular and respiratory conditions.
“Gilead is the leader in HIV, and fewer companies are working in HIV now,” said Andrew Cheng, executive vice present of clinical research and development operations.
The biotech company dominates the HIV market, estimating that about 80 percent of new patients starting therapy are prescribed a Gilead drug. GlaxoSmithKline PLC, AbbVie Inc. and Johnson & Johnson are competitors.
Gilead’s Viread, taken in combination with other drugs in four HIV therapies, will face generic competition in December 2017. To replace it, Gilead is rolling out a new set of treatments based on TAF, an improved version of Viread that achieves the same viral suppression with one-10th the dose, meaning fewer side effects to patients’ kidneys and bones. The TAF-based regimens are expected to start receiving approvals from U.S. regulators in November.
At the same time, Gilead is working to put the TAF drugs out of business as it pursues a cure. HIV is notoriously tricky to attack — current treatments suppress virus replication, but the wily virus hides out in latent, or “resting,” cells that the immune system can’t find. With current drugs, when a patient stops treatment, the sleeping cells roar back to life.
Gilead’s leading candidate for a cure, GS-9620, employs a tactic known as “kick and kill,” in which latent cells are stimulated into an active mode, Cheng said. Then, in theory, the immune system can recognize the infected cells and kill them.
In a study of monkeys presented in February, doses of GS-9620 corresponded with “blips” of viral activity that suggested resting cells were being “woken up,” Cheng said. The drug is now being tried in humans in an early-stage trial, with initial results expected in the first half of 2016.